Xeris Biopharma(XERS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 grew 43% year-over-year to nearly $86 million, while full-year revenue increased by 44% to $292 million [5][6][15] - Adjusted EBITDA for Q4 was $25.1 million, an improvement of $16.8 million compared to the previous year, with full-year adjusted EBITDA at $59.4 million [18][19] - The company achieved net income for the first time on a full-year basis in 2025, marking a significant milestone in financial performance [19] Business Line Data and Key Metrics Changes - Recorlev revenue was $45.3 million in Q4 and $139.3 million for the full year, reflecting over 100% growth for both periods, driven by an expanding patient base [16][17] - Gvoke generated $24.6 million in Q4 and $94.1 million for the year, with steady prescription growth and broad access contributing to its performance [16][17] - Keveyis revenue was $12.8 million in Q4 and $47.6 million for the year, supported by an increase in the average number of patients on therapy [17] Market Data and Key Metrics Changes - The patient base for Recorlev nearly doubled to approximately 700 patients by the end of 2025, reflecting increased prescriber awareness and confidence [7] - Gvoke remains a life-saving product for diabetes patients, with continued alignment with treatment guidelines supporting its growth [9] - Keveyis continues to serve a small, underserved patient community, aligning with the company's mission to make a meaningful difference in rare diseases [10] Company Strategy and Development Direction - The company aims for rapid revenue growth and plans to invest in sales, patient support, and commercial infrastructure [12][20] - XP-8121 is expected to enter Phase 3 trials in the second half of 2026, with potential peak sales of $1 billion to $3 billion [11][12] - The company is committed to maintaining a strong balance sheet while making disciplined investments to support growth [19][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and momentum entering 2026, expecting total revenue between $375 million and $390 million, representing over 30% growth at the midpoint compared to 2025 [13][20] - The company anticipates remaining adjusted EBITDA positive while significantly increasing R&D and commercial investments [20][22] - Management highlighted the importance of a strong operating foundation and the potential for sustained long-term growth [19][70] Other Important Information - The company filed a patent infringement lawsuit against two ANDA filers to protect Recorlev, with confidence in its intellectual property [8][62] - Management emphasized the need for ongoing investments in data studies and patient support to drive Recorlev's growth [26] Q&A Session Summary Question: Insights on Recorlev expansion and operating leverage - Management noted the doubling of the commercial footprint and the need for additional resources to manage patient loads effectively [26][27] Question: Impact of IP litigation on business development - Management stated that the strategy for Recorlev remains unchanged and they are prepared for the litigation [31][32] Question: Guidance on capital deployment beyond 2026 - Management indicated a strong balance sheet and the potential for business development opportunities while remaining disciplined [33][34] Question: Revenue guidance by product for 2026 - Management expects Keveyis to flatten out, Gvoke to grow in the high single-digit to low double-digit range, and Recorlev to be the primary growth driver [40][41] Question: Concerns about generic competition for Recorlev - Management does not see generic Korlym as a risk, emphasizing the different approaches required for prescribing [50] Question: Updates on XP-8121 and FDA interactions - Management confirmed alignment with the FDA and readiness to initiate Phase 3 trials without regulatory gating issues [53]